Liminatus Pharma (LIMN) said Friday it is exploring the formation of a $500 million digital asset investment subsidiary.
The proposed subsidiary, if approved, would operate separately from Liminatus's core clinical pipeline and focus on digital asset allocation and blockchain-integrated financial structures, the company said.
Liminatus said potential capital formation could involve private placements, convertible instruments, equity line, and other structured financing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.